Biotechnology Trade Secret Law In Russia.

1. Introduction

Biotechnology Trade Secret Law in Russia concerns the legal protection of confidential scientific, technical, commercial and industrial information used in biotechnology research, pharmaceutical manufacturing, genetic engineering, biological products, vaccine development, tissue engineering, molecular diagnostics and other life-science industries.

Biotechnology companies frequently develop valuable information that is not publicly disclosed, including:

Gene-editing techniques and CRISPR-related processes.

DNA sequencing methods and genetic testing protocols.

Pharmaceutical formulas and biological compositions.

Vaccine manufacturing processes and production techniques.

Cell-culture conditions and tissue-engineering procedures.

Microorganism strains and fermentation processes.

Clinical-trial information and experimental research results.

Bioprocessing parameters and quality-control methods.

Proprietary algorithms used in genomic and biomedical research.

Russian law protects qualifying confidential commercial and technical information primarily through the concept of production secrets (know-how), alongside the general legal regime governing trade secrets.

The principal legislation is Part IV of the Russian Civil Code, particularly Articles 1465–1472, and Federal Law No. 98-FZ of 29 July 2004, On Commercial Secrets.

The central legal objective is to prevent unauthorized acquisition, disclosure and commercial exploitation of valuable confidential information while preserving legitimate scientific research, employee mobility, competition and public-health interests.

2. Legal Framework Governing Biotechnology Trade Secrets

Russia does not rely on a single biotechnology-specific trade secret statute. Instead, biotechnology information is protected through several overlapping legal instruments.

A. Civil Code of the Russian Federation

Part IV of the Civil Code establishes the intellectual-property framework for production secrets.

The most important provisions are:

ProvisionLegal significance
Article 1225Recognizes production secrets (know-how) as protected intellectual-property subject matter.
Article 1229Establishes the general framework for exclusive intellectual-property rights.
Article 1235Regulates intellectual-property licence agreements.
Article 1465Defines production secrets (know-how).
Article 1466Establishes the exclusive right to production secrets.
Article 1467Governs the duration of exclusive rights.
Article 1468Regulates contractual disposal of exclusive rights.
Article 1469Regulates licensing of production secrets.
Article 1470Addresses production secrets created by employees.
Article 1471Addresses production secrets created under contractual arrangements.
Article 1472Establishes liability for infringement of exclusive rights.

Article 1465 is particularly important. It protects information of a technical, economic, organizational or other nature where:

The information has actual or potential commercial value because it is unknown to third parties.

Third parties do not have lawful free access to it.

The information's owner has introduced a reasonable confidentiality regime.

For biotechnology companies, these requirements mean that merely labelling research information as confidential is insufficient. The company must take meaningful steps to preserve secrecy.

B. Federal Law No. 98-FZ of 29 July 2004

The Federal Law On Commercial Secrets establishes the organizational and administrative framework for protecting confidential commercial information.

It addresses:

Identification of commercial secrets.

Restrictions on access.

Confidentiality obligations.

Employee responsibilities.

Documentation of access.

Protection against unauthorized disclosure.

Legal consequences of confidentiality violations.

For a biotechnology enterprise, this legislation is important because research information is frequently shared between scientists, laboratories, pharmaceutical manufacturers, universities, contractors and investors.

C. Criminal Code of the Russian Federation

Article 183 addresses unlawful acquisition and disclosure of information constituting commercial, tax or banking secrets.

Depending on the circumstances, criminal liability may arise from unlawful collection, disclosure or use of protected information.

For example, an employee who deliberately transfers confidential vaccine-production information to an unauthorized competitor may potentially face criminal investigation if the statutory elements are satisfied.

D. Additional Applicable Legislation

Other legal instruments may apply depending on the information and activities involved:

Federal Law No. 149-FZ of 27 July 2006, concerning information, information technologies and information protection.

Federal Law No. 152-FZ of 27 July 2006, concerning personal data.

Federal Law No. 61-FZ of 12 April 2010, concerning the circulation of medicines.

Federal Law No. 323-FZ of 21 November 2011, concerning the fundamentals of health protection.

Federal Law No. 86-FZ of 5 July 1996, concerning the regulation of genetic engineering activities.

These laws may impose confidentiality, information-security, safety or disclosure requirements that interact with trade secret protection.

3. What Biotechnology Information Qualifies as a Trade Secret?

Not every scientific discovery or laboratory document automatically qualifies for protection. The information must satisfy the statutory requirements of Article 1465.

A. Genetic engineering and gene-editing information

A biotechnology company may protect confidential information concerning:

CRISPR-Cas9 editing protocols.

Gene-expression optimization.

Laboratory-developed genetic modification processes.

Proprietary DNA assembly techniques.

Methods of improving gene-editing efficiency.

For example, a company developing a gene-editing platform may maintain its precise laboratory procedures, reagent combinations and optimization parameters as know-how.

However, information already lawfully available to the public cannot ordinarily be monopolized through trade secret protection.

B. Pharmaceutical formulations

Confidential pharmaceutical information may include:

Drug formulation compositions.

Stabilization techniques.

Active ingredient combinations.

Manufacturing temperatures and processing parameters.

Biological product purification methods.

A pharmaceutical manufacturer may protect a confidential formulation even when the finished medicine is commercially available, provided the underlying information remains secret and satisfies Article 1465.

C. Vaccine development and manufacturing

Vaccine technology is particularly relevant to Russian trade secret law.

Potentially protected information includes:

Antigen-production techniques.

Cell-culture conditions.

Viral-vector manufacturing procedures.

Purification processes.

Formulation and stabilization parameters.

Proprietary quality-control methods.

However, public-health disclosure requirements, regulatory submissions and other mandatory disclosure obligations may limit the scope of protection.

D. Genomic and diagnostic technologies

Confidential biotechnology information may include:

Proprietary sequencing workflows.

Diagnostic assay procedures.

Biomarker detection methods.

Laboratory-developed testing processes.

Bioinformatics algorithms.

Genetic data-processing techniques.

A company must distinguish confidential technical know-how from personal genetic information. Genetic information concerning identifiable individuals may also be subject to Russian personal-data legislation.

4. Establishment of a Trade Secret Protection Regime

One of the most important legal issues is the establishment of an effective confidentiality system.

Under Article 10 of Federal Law No. 98-FZ, the holder of commercial secrets must take prescribed measures to protect confidential information.

These measures include:

Identifying the information that constitutes a commercial secret.

Restricting access through established procedures.

Maintaining records of persons who have received access to confidential information.

The legislation also provides for contractual and technical confidentiality safeguards.

Practical requirements for biotechnology companies

A biotechnology research organization should establish:

Protection mechanismPractical application
Confidentiality policyIdentifies protected scientific information.
Access restrictionsLimits laboratory and database access.
Employee agreementsEstablishes confidentiality obligations.
Laboratory securityProtects samples, records and research facilities.
Digital securityRestricts unauthorized downloading and copying.
NDA agreementsRegulates disclosure to commercial partners.
Research documentationRecords the development and ownership of know-how.
Access registersIdentifies individuals who received confidential information.

Important legal distinction: Since 1 October 2014, Article 1465 does not require the formal commercial-secret regime to be the exclusive method of preserving confidentiality. The Supreme Court clarified that reasonable confidentiality measures can be sufficient. Nevertheless, implementing the statutory commercial-secret regime provides an important evidentiary foundation.

This distinction is especially important for research laboratories that collaborate with universities, hospitals and foreign pharmaceutical companies.

Consultant Plus+2

 

5. Ownership of Biotechnology Trade Secrets

Ownership is a major issue because biotechnology research frequently involves several participants.

A. Ownership by biotechnology companies

A company may hold exclusive rights in know-how developed through its research and development activities.

For example, a pharmaceutical company independently develops a confidential biological manufacturing technique and implements appropriate confidentiality safeguards.

The company may qualify as the right holder under Article 1465.

B. Employee-created biotechnology know-how

Article 1470 regulates employee-created production secrets.

Where an employee creates qualifying know-how while performing employment duties or a specific employer assignment, the exclusive right generally belongs to the employer.

For example:

A scientist working for a Russian pharmaceutical company develops a confidential vaccine purification technique as part of assigned research duties.

If the legal requirements of Article 1470 are satisfied, the employer obtains the exclusive right.

The employment contract, job description, research assignment, laboratory records and confidentiality agreements become important evidence.

C. University and research-institute ownership

Biotechnology research conducted through universities and scientific institutes may involve:

University researchers.

Government-funded research institutions.

Private pharmaceutical sponsors.

Research contractors.

Foreign scientific collaborators.

Article 1471 and applicable contractual arrangements must be considered when determining ownership of know-how developed through contracted research.

Research agreements should expressly identify:

Background intellectual property.

Newly developed know-how.

Ownership of research results.

Rights to publish scientific findings.

Confidentiality obligations.

Licensing and commercialization rights.

D. Joint biotechnology research

Where several organizations cooperate, the parties should define ownership and permitted use before research begins.

For example, a Russian university and a pharmaceutical company may jointly develop a new cell-culture process.

Their agreement should distinguish each party's pre-existing technology from the newly developed confidential information.

rospatent.gov.ru+2

6. Licensing and Commercialization of Biotechnology Trade Secrets

Russian law permits biotechnology trade secrets to be commercially exploited through licensing and assignment.

A. Know-how licensing under Article 1469

Article 1469 governs agreements granting the right to use production secrets.

A biotechnology licensing agreement may cover:

Pharmaceutical manufacturing techniques.

Vaccine-production protocols.

Genetic testing methods.

Cell-culture procedures.

Bioprocessing technologies.

Confidential diagnostic algorithms.

The agreement should identify the protected know-how sufficiently clearly to distinguish it from general scientific knowledge.

It should also establish:

Scope of authorized use.

Territory of commercialization.

Duration of the licence.

Licensing fees and royalties.

Permitted sublicensing.

Confidentiality obligations.

Security and audit requirements.

Consequences of unauthorized disclosure.

B. Assignment under Article 1468

Article 1468 permits the transfer of the exclusive right to production secrets.

For example, a Russian biotechnology company may transfer its confidential manufacturing technology to another pharmaceutical enterprise.

The transferring right holder must continue preserving confidentiality until the exclusive right terminates.

C. Duration under Article 1467

Unlike patent protection, know-how protection does not have a predetermined statutory term.

The exclusive right continues as long as the information remains confidential.

Once confidentiality is lost, the exclusive right terminates.

This creates a significant commercial advantage for biotechnology companies possessing valuable manufacturing information that they prefer not to disclose through patent publication.

rospatent.gov.ru+1

7. Case Laws and Judicial Interpretation

Russian courts have developed important principles concerning the protection, licensing, ownership and unauthorized exploitation of production secrets.

The following decisions are particularly relevant to biotechnology trade secret disputes.

Case 1: Intellectual Property Rights Court, 11 October 2018, No. С01-808/2018, Case No. А56-53278/2017

Direct biotechnology relevance

Subject: Unauthorized use of vaccine manufacturing technology

This is particularly important for biotechnology trade secret law because the dispute concerned information relating to a vaccine-production technology.

The claimant sought to prohibit the defendant from using the disputed production secret and to recover damages.

The Intellectual Property Rights Court upheld the lower courts' refusal to grant the requested relief.

The courts considered that the defendant's use and disposal of information relating to the vaccine manufacturing technology had occurred with the claimant's knowledge and consent.

Consequently, the circumstances did not establish the necessary grounds for imposing liability for infringement of the exclusive right.

Legal principles:

Vaccine manufacturing technology can constitute protected production know-how.

The circumstances in which confidential information was shared are legally significant.

Consent to use confidential technology may defeat a claim of unauthorized exploitation.

A claimant must establish an actual infringement rather than rely solely on the confidential nature of the information.

Importance for biotechnology: Pharmaceutical and vaccine companies should carefully document permissions, technical transfers and authorized uses of manufacturing know-how.

Документы ленты ПРАЙМ: ГАРАНТ.РУ

Case 2: Supreme Court of the Russian Federation, Plenum Resolution No. 10 of 23 April 2019

Subject: Legal protection of production secrets and reasonable confidentiality measures

Paragraphs 143–145 provide important judicial guidance concerning Article 1465.

The Supreme Court explained that know-how protection applies to commercially valuable information that:

Is unknown to third parties.

Is not freely accessible on lawful grounds.

Has actual or potential commercial value.

Is subject to reasonable confidentiality measures.

Paragraph 144 is particularly significant.

It clarifies that, since 1 October 2014, the introduction of a formal commercial-secret regime is not the only permissible way to preserve confidentiality.

Paragraph 145 also explains that liability under Article 1472 may extend to any person who unlawfully discloses protected know-how or otherwise infringes the exclusive right, including public-law entities in appropriate circumstances.

Importance for biotechnology: A company defending its proprietary gene-editing methods, vaccine formulations or pharmaceutical manufacturing procedures must demonstrate the actual confidentiality measures it implemented.

VSRF

Case 3: Arbitration Court, Case No. А60-1432/2023, Decision of 29 May 2023

Subject: Proof of ownership and existence of know-how

This case concerned a claim involving recipes for organic additives and a technological production process.

The claimant was unable to provide sufficient relevant and admissible evidence establishing the existence of the claimed exclusive rights in the disputed information.

The court emphasized that information only acquires the status of protected know-how when the statutory requirements are fulfilled.

It also considered the importance of proving the claimant's ownership and the defendant's infringement.

Legal principles:

A description of a technology does not automatically establish exclusive rights.

The claimant must establish the existence of the protected know-how.

The claimant must establish ownership or entitlement to the exclusive right.

Evidence of infringement is essential.

Importance for biotechnology: A biotechnology company should maintain dated research records, technical specifications, access logs, confidentiality agreements and documents establishing the development of proprietary processes.

Sudact

Case 4: Arbitration Court, Case No. А33-14329/2021, Decision of 18 July 2022

Subject: Contractual transfer and exploitation of know-how

This dispute concerned contractual exploitation of a package of exclusive rights that included production know-how.

The court examined arguments concerning the absence of a physical medium containing the confidential information and the alleged failure to establish a commercial-secret regime.

The appellate court did not accept the argument that the absence of a physical medium automatically invalidated the transfer.

It also considered the contractual circumstances and the actual exploitation of the transferred rights.

Legal principles:

Know-how can be transferred through contractual arrangements.

Physical delivery of a document is not invariably necessary.

The contractual scope of transferred rights matters.

The parties' conduct and actual use of the technology may be relevant.

Importance for biotechnology: Digital transfer of confidential laboratory protocols, technical databases and manufacturing instructions should be expressly addressed in licensing agreements.

Sudact

Case 5: Arbitration Court, Case No. А07-21095/2023, Decision of 30 January 2025

Subject: Commercial value and licensing of production secrets

The court considered a dispute involving a licence agreement for production know-how.

The judgment discussed Article 1465 and the Supreme Court's 2019 interpretation of the requirements for protected production secrets.

It also addressed the licensee's contractual obligation to pay remuneration for the use of the licensed information.

Legal principles:

A know-how licensing arrangement must satisfy the relevant statutory requirements.

The existence of a licence agreement does not eliminate the need to establish the nature of the licensed information.

Contractual payment obligations must be performed in accordance with the agreement and applicable law.

Importance for biotechnology: Licensing agreements for pharmaceutical formulas, laboratory procedures and cell-culture technology should identify the licensed technical information with sufficient precision.

Sudact

8. Legal Liability for Misappropriation of Biotechnology Trade Secrets

Russian law provides several forms of legal responsibility for unlawful acquisition, disclosure or exploitation of confidential biotechnology information.

A. Civil liability under Article 1472

Article 1472 of the Civil Code establishes liability for infringement of exclusive rights to production secrets.

A person who unlawfully discloses or uses protected know-how may be required to compensate the right holder for losses.

Examples include:

A former employee disclosing a pharmaceutical formulation.

A competitor unlawfully acquiring vaccine-production procedures.

A contractor transferring confidential genetic-engineering protocols.

A research partner using proprietary cell-culture technology outside the licence.

The claimant must establish the relevant protected right, infringement and legally required elements of the compensation claim.

B. Injunctive relief

Under the general intellectual-property enforcement framework, particularly Article 1252, a right holder may seek appropriate judicial remedies.

Depending on the circumstances, these can include:

Stopping unauthorized use.

Preventing further disclosure.

Removing infringing materials from circulation where legally appropriate.

Seeking compensation for established losses.

Obtaining other remedies provided by law.

For biotechnology companies, an injunction can be especially important where disclosure of a manufacturing process would permanently destroy its commercial secrecy.

C. Criminal liability under Article 183

Article 183 of the Russian Criminal Code criminalizes specified forms of unlawful acquisition, disclosure and use of commercial secrets.

Its application depends on the precise statutory elements and the circumstances of the offence.

ConductPotential legal consequence
Unlawful collection of commercial secretsCriminal liability under Article 183(1).
Unauthorized disclosure by a person entrusted with confidential informationCriminal liability under Article 183(2).
Conduct involving a group, substantial damage or financial motivationMore serious liability under Article 183(3).
Conduct causing grave consequencesLiability under Article 183(4).

The penalties include fines, compulsory or corrective work, restrictions on professional activities and imprisonment, depending on the applicable provision.

For example, an employee who unlawfully transfers confidential vaccine-production information to a competitor may face criminal proceedings if the requirements of Article 183 are established.

Consultant Plus+1

D. Employment-related liability

Biotechnology employees may also face employment consequences.

Relevant provisions include:

Article 81 of the Labour Code: Grounds for termination of employment, including specified confidentiality-related violations.

Article 192: Disciplinary sanctions.

Article 238: Employee material liability for direct actual damage.

Article 243: Cases of full material liability.

An employer must satisfy the relevant procedural and substantive requirements. An accusation of disclosure alone does not automatically establish grounds for dismissal or full financial liability.

9. Exceptions and Limitations on Trade Secret Protection

Trade secret protection is not absolute.

A. Publicly available scientific information

A biotechnology company cannot claim exclusive trade secret protection over scientific information that is already lawfully accessible to the public.

For example, a gene-editing technique published in a scientific journal cannot ordinarily be monopolized as confidential know-how merely because another company later uses it.

B. Independently developed technology

Article 1466 recognizes that a person who independently and in good faith obtains the information constituting protected know-how can acquire an independent exclusive right.

Consequently, Russian law does not automatically prohibit independent scientific discovery.

C. Reverse engineering

Independent acquisition of know-how through lawful research or permitted reverse engineering must be distinguished from unlawful acquisition.

A competitor's independent development of a biological production technique is not automatically infringement.

D. Mandatory regulatory disclosure

Article 1465(2) excludes information whose mandatory disclosure, or unrestricted accessibility, is established by law or another legal act.

Biotechnology companies must therefore distinguish genuinely confidential technical information from information that must be provided to regulatory authorities or disclosed under applicable law.

E. Public-health interests

Commercial secrecy cannot be used to defeat applicable public-health, safety or statutory disclosure requirements.

Federal Law No. 98-FZ also restricts the use of commercial-secret protection in circumstances contrary to constitutional principles and the protection of health and legitimate interests.

Consultant Plus+2

10. Biotechnology Trade Secrets and Patent Protection in Russia

One important strategic question is whether biotechnology companies should protect their innovations through patents or trade secrets.

Legal issuePatent protectionTrade secret protection
RegistrationRequires patent application and examinationNo patent registration required
DisclosureRequires disclosure of the inventionInformation remains confidential
DurationGenerally limited statutory termContinues while secrecy exists
Independent discoveryPatent rights may restrict commercial exploitationIndependent acquisition is recognized
Reverse engineeringPatent rights may restrict covered activitiesLawful independent discovery may be permitted
EnforcementBased on patent infringementBased on unlawful acquisition, disclosure or use
Biotechnology applicationPatentable inventions and processesConfidential manufacturing and research know-how

Example: CRISPR biotechnology

Suppose a Russian biotechnology company develops a new gene-editing platform.

It could consider:

Patenting a qualifying technical invention.

Keeping confidential laboratory optimization procedures as know-how.

Protecting proprietary manufacturing parameters through confidentiality agreements.

Licensing the technology under Articles 1468 or 1469.

Restricting access to sensitive research databases.

The company must assess patentability, disclosure consequences and the possibility of independent development before choosing its protection strategy.

11. Cross-Border Biotechnology Trade Secret Protection

Russian biotechnology companies increasingly participate in international research, pharmaceutical licensing and scientific cooperation.

Cross-border transactions create additional legal risks.

A. Foreign pharmaceutical partnerships

A Russian company may disclose confidential pharmaceutical manufacturing information to a foreign commercial partner.

The agreement should specify:

Ownership of existing and newly developed know-how.

Permitted purposes of disclosure.

Restrictions on onward transfer.

Confidentiality obligations.

Applicable law and dispute-resolution mechanisms.

Procedures for returning or destroying confidential information.

B. International research collaboration

Universities and laboratories may exchange genetic engineering protocols, biological samples and research findings.

Research agreements should distinguish confidential technical information from research results intended for scientific publication.

C. Foreign employee and contractor access

Where foreign researchers receive access to Russian biotechnology information, organizations should establish appropriate contractual and technical safeguards.

They should also consider applicable export-control, sanctions, data-protection and biosecurity requirements.

D. International intellectual-property protection

Article 39 of the WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) establishes international standards for protecting undisclosed information.

It requires qualifying information to be protected against acquisition, disclosure or use contrary to honest commercial practices.

However, the precise international obligations applicable to a particular transaction must be assessed in light of the relevant jurisdiction, treaty participation and domestic law.

WIPO+1

12. Major Legal Challenges in Russian Biotechnology Trade Secret Law

Several challenges arise when applying general trade secret legislation to modern biotechnology.

1. AI-generated biotechnology research

AI systems can generate new molecular designs, pharmaceutical candidates and genetic-analysis methods. Determining ownership of confidential information generated through AI-assisted research may require examination of employment arrangements, contractual rights and applicable intellectual-property rules.

2. Genetic information protection

Biotechnology companies may possess both confidential commercial information and sensitive personal genetic information. These are legally distinct categories and may require separate protection under Federal Law No. 152-FZ.

3. Biobank confidentiality

Tissue banks and genetic repositories may contain valuable research protocols, sample-processing methods and confidential commercial information. Their protection must be distinguished from the legal rules governing biological samples and personal data.

4. Employee mobility

Scientists frequently move between pharmaceutical companies and research institutions. Russian law must balance the employer's exclusive rights in protected know-how with employees' ability to use their general professional knowledge and independently acquired skills.

5. Commercialization of publicly funded research

Government-funded biotechnology projects can create disputes over ownership, commercialization rights and the disclosure of research results.

6. Confidentiality versus scientific publication

Researchers may wish to publish findings in scientific journals. Premature publication can destroy the confidentiality required for know-how protection and may also affect patentability.

7. Digital theft of research information

Cyberattacks, unauthorized cloud access, stolen laboratory databases and unlawful transfers of genomic research files create new enforcement challenges.

13. Recommendations for Biotechnology Companies Operating in Russia

A biotechnology organization should implement an integrated legal and technical protection programme.

Recommended compliance framework

Identify confidential information

Prepare a detailed register of protected formulas, laboratory procedures, research data and manufacturing processes.

Establish confidentiality measures

Introduce appropriate commercial-secret procedures under Federal Law No. 98-FZ.

Protect employee-created know-how

Define employment duties, research assignments and ownership under Article 1470.

Execute NDAs

Require appropriate confidentiality agreements for researchers, contractors and commercial partners.

Secure research infrastructure

Use access controls, encryption, monitoring and secure laboratory records.

Regulate technology licensing

Draft clear agreements under Articles 1468 and 1469.

Maintain evidence

Preserve research notebooks, development records, access histories and technical documentation.

Establish an incident-response procedure

Develop procedures for investigating suspected theft, preserving evidence and pursuing civil or criminal remedies.

14. Conclusion

Biotechnology Trade Secret Law in Russia provides an important framework for protecting confidential scientific and commercial information.

The central legal foundation consists of Articles 1465–1472 of the Civil Code and Federal Law No. 98-FZ of 29 July 2004.

These provisions allow biotechnology enterprises to protect commercially valuable information relating to genetic engineering, pharmaceutical formulations, vaccine manufacturing, tissue engineering, molecular diagnostics and biological production processes.

The most important judicial principles emerge from the Intellectual Property Rights Court's 2018 vaccine-technology decision, Supreme Court Plenum Resolution No. 10 of 23 April 2019, and subsequent arbitration decisions concerning the proof, licensing and exploitation of know-how.

The fundamental principle is that biotechnology information receives trade secret protection only when the statutory requirements are fulfilled and the holder takes reasonable measures to preserve its confidentiality.

Russian law therefore attempts to balance commercial innovation, scientific cooperation, employee rights, fair competition and public-health interests.

15. Important Legal Sources and Case Law for Further Research

AuthorityRelevance
Civil Code, Articles 1465–1472Core production-secret legislation
Federal Law No. 98-FZ (2004)Commercial-secret protection
Criminal Code, Article 183Criminal protection
Supreme Court Plenum Resolution No. 10 (2019)Judicial interpretation of know-how
Intellectual Property Rights Court, С01-808/2018, А56-53278/2017Vaccine manufacturing technology
Case А60-1432/2023 (2023)Proof of know-how ownership
Case А33-14329/2021 (2022)Contractual transfer of know-how
Case А07-21095/2023 (2025)Know-how licensing and commercial value

Primary research materials:

Russian Civil Code, Part IV – English text.

Federal Law No. 98-FZ – WIPO Lex.

Supreme Court Plenum Resolution No. 10 of 2019.

Vaccine manufacturing technology judgment – Case А56-53278/2017.

Russian Criminal Code – Article 183.

Arbitration judgment – Case А60-1432/2023.

Research note: The vaccine judgment is directly related to biotechnology. The other cited arbitration decisions concern general know-how principles and are useful by analogy; they should not be represented as biotechnology-specific precedents. This is an academic legal overview, not an opinion on a particular dispute. Russian statutory references should be checked against the consolidated legislation applicable on the date of the relevant transaction or litigation.

LawGratis provides pro bono legal aid and resources to empower communities. Join us in making justice reachable for everyone! Follow our community on Instagram, YouTube, Facebook, and LinkedIn.

LEAVE A COMMENT